keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant endocrine therapy

keyword
https://www.readbyqxmd.com/read/27919974/a-phase-ii-study-of-adjuvant-chemotherapy-of-tegafur-uracil-for-patients-with-breast-cancer-with-her2-negative-pathologic-residual-invasive-disease-after-neoadjuvant-chemotherapy
#1
Satoru Tanaka, Mitsuhiko Iwamoto, Kosei Kimura, Yuko Takahashi, Hiyoya Fujioka, Nayuko Sato, Risa Terasawa, Kanako Kawaguchi, Ayana Ikari, Tomo Tominaga, Saki Maezawa, Nodoka Umezaki, Junna Matsuda, Kazuhisa Uchiyama
BACKGROUND: There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. PATIENTS AND METHODS: We treated patients with 270 mg/m(2) UFT per day for 2 years after definitive surgery and radiotherapy, if necessary...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27915204/powerpiinc-preoperative-window-of-endocrine-therapy-provides-information-to-increase-compliance-trial-changes-in-tumor-proliferation-index-and-quality-of-life-with-7-days-of-preoperative-tamoxifen
#2
Adam L Cohen, Rachel E Factor, Kathi Mooney, Mohamed E Salama, Mark Wade, Victoria Serpico, Emily Ostrander, Edward Nelson, Jane Porretta, Cindy Matsen, Philip Bernard, Ken Boucher, Leigh Neumayer
OBJECTIVES: A decrease in Ki67 during neoadjuvant therapy predicts response to tamoxifen. Previous trials have shown a decreased Ki67 in breast tumors with as little as two or more weeks of preoperative tamoxifen. Shortening the preoperative treatment time in window of opportunity clinical trials makes these trials more attractive to women. POWERPIINC examined the effect of 7 days of preoperative tamoxifen on breast tumor proliferation and patient symptoms. METHODS: Women with untreated stage I/II, ER-positive, invasive breast cancer with no contraindications to tamoxifen were enrolled...
December 1, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27903675/a-pam50-based-chemo-endocrine-score-for-hormone-receptor-positive-breast-cancer-with-an-intermediate-risk-of-relapse
#3
Aleix Prat, Ana Lluch, Arran K Turnbull, Anita K Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montse Muñoz, Laia Paré, Joel S Parker, Nuria Ribelles, Begona Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva M Carrasco, Miguel Martín, J Michael Dixon, Charles M Perou, Emilio Alba
PURPOSE: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous and subgroups with different prognostic and treatment sensitivities need to be identified. EXPERIMENTAL DESIGN: Research-based PAM50 subtyping and expression of additional genes was performed on 63 patients with HR+/HER2- disease randomized to neoadjuvant multi-agent chemotherapy versus endocrine therapy in a phase II trial. The biology associated with treatment response was used to derive a PAM50-based Chemo-Endocrine Score (CES)...
November 30, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27903276/accurate-prediction-of-response-to-endocrine-therapy-in-breast-cancer-patients-current-and-future-biomarkers
#4
REVIEW
Cigdem Selli, J Michael Dixon, Andrew H Sims
Approximately 70% of patients have breast cancers that are oestrogen receptor alpha positive (ER+) and are therefore candidates for endocrine treatment. Many of these patients relapse in the years during or following completion of adjuvant endocrine therapy. Thus, many ER+ cancers have primary resistance or develop resistance to endocrine therapy during treatment. Recent improvements in our understanding of how tumours evolve during treatment with endocrine agents have identified both changes in gene expression and mutational profiles, in the primary cancer as well as in circulating tumour cells...
December 1, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27866067/escalating-and-de-escalating-treatment-in-her2-positive-early-breast-cancer
#5
REVIEW
Heikki Joensuu
The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of chemotherapy plus 12months of trastuzumab, with or without endocrine therapy. Several trials have investigated modifications of the standard treatment that are shorter and less resource-demanding (de-escalation) or regimens that aim at dual HER2 inhibition or include longer than 12months of HER2-targeted treatment (escalation). Seven randomized trials investigate shorter than 12months of trastuzumab treatment duration...
November 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27865536/breast-cancer
#6
REVIEW
Nadia Harbeck, Michael Gnant
Breast cancer is one of the three most common cancers worldwide. Early breast cancer is considered potentially curable. Therapy has progressed substantially over the past years with a reduction in therapy intensity, both for locoregional and systemic therapy; avoiding overtreatment but also undertreatment has become a major focus. Therapy concepts follow a curative intent and need to be decided in a multidisciplinary setting, taking molecular subtype and locoregional tumour load into account. Primary conventional surgery is not the optimal choice for all patients any more...
November 16, 2016: Lancet
https://www.readbyqxmd.com/read/27817858/-systemic-neoadjuvant-therapy-of-luminal-breast-cancer-in-2016
#7
REVIEW
Paul H Cottu
Neoadjuvant systemic therapies have been extensively evaluated in luminal breast cancer. Conventional cytotoxic chemotherapy increases breast conservation rate, albeit with a low level of complete pathological response of uncertain clinical significance. Endocrine therapies allow similar clinical results with much less side effects. Biological criteria of response to endocrine therapies are still being defined. The neoadjuvant setting must be used for early development of new compounds and to further document biological mechanisms of sensitivity and resistance to treatments...
November 3, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27788894/neoadjuvant-systemic-therapy-use-for-younger-patients-with-breast-cancer-treated-in-different-types-of-cancer-centers-across-the-united-states
#8
Jahan J Mohiuddin, Allison M Deal, Lisa A Carey, Jennifer L Lund, Brock R Baker, Timothy M Zagar, Ellen L Jones, Lawrence B Marks, Ronald C Chen
BACKGROUND: Multiple clinical trials have shown that neoadjuvant systemic therapy has a benefit in women who are borderline lumpectomy candidates and in those with locally advanced breast cancers by reducing the mastectomy rate and making inoperable tumors operable. The study aim was to examine the patterns of neoadjuvant chemotherapy and endocrine therapy use among younger women in the United States treated at different types of cancer centers. STUDY DESIGN: Data from the National Cancer Data Base for 118,086 women younger than 65 years with clinical stage IIA (T2N0 only) to IIIC breast cancer...
November 2016: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/27770345/chemosensitivity-and-endocrine-sensitivity-in-clinical-luminal-breast-cancer-patients-in-the-prospective-neoadjuvant-breast-registry-symphony-trial-nbrst-predicted-by-molecular-subtyping
#9
Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V Pellicane, Charles Nash, Mary Murray, Laura A Lee, Carrie L Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A de Snoo, Jennifer Beatty
PURPOSE: Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for determining optimal treatment. In the Neoadjuvant Breast Registry Symphony Trial (NBRST) patients were classified according to MammaPrint/BluePrint subtyping to provide insight into the response to neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NCT). OBJECTIVE: The purpose of this predefined substudy was to compare MammaPrint/BluePrint with conventional 'clinical' immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) subtyping in 'clinical luminal' [HR+/human epidermal growth factor receptor 2-negative (HER2-)] breast cancer patients to predict treatment sensitivity...
October 21, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27757718/outcomes-of-patients-with-inflammatory-breast-cancer-treated-by-breast-conserving-surgery
#10
Monika Brzezinska, Linda J Williams, Jeremy Thomas, J Michael Dixon
PURPOSE: Inflammatory breast cancer (IBC) is rare and associated with a poor prognosis. Following neoadjuvant chemotherapy or endocrine therapy, the multidisciplinary team selected a small number of patients for breast-conservation therapy (BCT). The aim of this study was to determine the outcome of IBC patients treated with BCT in Edinburgh. METHODS: Between January 1999 and December 2013, thirty-five women with IBC were treated by BCT. The median follow-up was 80 months...
October 18, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27741213/systemic-therapies-for-nonmetastatic-breast-cancer-the-role-of-neoadjuvant-and-adjuvant-chemotherapy-and-the-use-of-endocrine-therapy
#11
Brittany L Bychkovsky, Don S Dizon, William M Sikov
Breast cancer is a heterogenous disease, comprised of at least 3 major subtypes: hormone receptor-positive/HER2-(HR+), HER2+, and HR-/HER2-(triple negative) breast cancers. The medical management of each subype is distinct. In this article, we review contemporary data supporting the use of chemotherapy, endocrine therapy and biologic therapies, especially HER2-directed agents, in the adjuvant and neoadjuvant setting in patients with newly diagnosed nonmetastatic (stage I-III) breast cancer.
December 2016: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27688475/a-randomized-feasibility-study-of-18f-fluoroestradiol-positron-emission-tomography-to-predict-pathological-response-to-neoadjuvant-systemic-therapy-in-estrogen-receptor-rich-postmenopausal-breast-cancer
#12
Sun Young Chae, Sung-Bae Kim, Sei Hyun Ahn, Hye Ok Kim, Dok Hyun Yoon, Jin-Hee Ahn, Kyung Hae Jung, Sangwon Han, Seung Jun Oh, Sang Ju Lee, Hee Jeong Kim, Byung Ho Son, Gyungyub Gong, Hyo Sang Lee, Dae Hyuk Moon
: The aim of this study was to explore the ability of (18)F-fluoroestradiol ((18)F-FES) positron emission tomography/computed tomography (PET/CT) imaging to predict pathologic response to neoadjuvant therapy in postmenopausal women with estrogen receptor (ER)-rich breast cancer. METHODS: This was a prospective, single-center study conducted as a sub-study of the neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer (NEOCENT) trial...
September 29, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27663568/trends-in-neoadjuvant-endocrine-therapy-use-and-impact-on-rates-of-breast-conservation-in-hormone-receptor-positive-breast-cancer-a-national-cancer-data-base-study
#13
Akiko Chiba, Tanya L Hoskin, Courtney N Heins, Kelly K Hunt, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS. METHODS: Using the National Cancer Data Base (NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancer patients age ≥50 years from 2004 to 2012...
September 23, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27628678/post-relapse-survival-in-patients-with-the-early-and-late-distant-recurrence-in-estrogen-receptor-positive-her2-negative-breast-cancer
#14
Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
BACKGROUND: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. METHODS: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions...
September 15, 2016: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/27627573/pet-ct-imaging-for-monitoring-recurrence-and-evaluating-response-to-treatment-in-breast-cancer
#15
REVIEW
Lei Lei, Xiaojia Wang, Zhanhong Chen
Monitoring recurrence and evaluating response to therapy are important aspects of clinical decision making in the treatment of breast cancer. In this literature review, the authors highlight several of the key areas where integrated fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) measurements are anticipated to have a significant impact on monitoring recurrence and evaluating response to therapy. These areas include comparing FDG PET/CT with conventional imaging for detecting breast cancer metastases; evaluating the role of FDG PET/CT in the presence of elevated tumor markers during follow-up period after the primary surgery; using FDG PET/CT to assess response to neoadjuvant chemotherapy (NAC), targeted and endocrine therapies; using FDG PET/CT to predict response to NAC according to different molecular phenotypes of breast cancer; and applying PET/CT and some new breast-related PET tracers to evaluate response to anticancer treatment...
March 2016: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/27473079/the-relationship-between-the-expression-of-foxa1-and-gata3-and-the-efficacy-of-neoadjuvant-endocrine-therapy
#16
Kimihiro Tanaka, Eriko Tokunaga, Nami Yamashita, Yasuaki Sagara, Yasuyo Ohi, Kenichi Taguchi, Shinji Ohno, Shinji Okano, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: Estrogen receptor (ER)/GATA3/Forkhead box A1 (FOXA1) network is necessary for the ERα functional signature. High FOXA1 expression indicates a good prognosis in ER-positive breast cancer. However, little is known about the significance of FOXA1 and GATA3 expression in neoadjuvant endocrine therapy (NAE). The aim of this study is to investigate their predictive potential for NAE and their expression changes after NAE. METHODS: FOXA1 and GATA3 expression was evaluated using immunohistochemistry in 66 patients with ER-positive/HER2-negative breast cancer who had been treated with NAE...
July 29, 2016: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/27367583/neoadjuvant-endocrine-therapy-for-estrogen-receptor-positive-breast-cancer-a-systematic-review-and-meta-analysis
#17
Laura M Spring, Arjun Gupta, Kerry L Reynolds, Michele A Gadd, Leif W Ellisen, Steven J Isakoff, Beverly Moy, Aditya Bardia
Importance: Estrogen receptor-positive (ER+) tumors of the breast are generally highly responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant treatment for ER+ breast cancer, the role of endocrine therapy in the neoadjuvant setting is unclear. Objective: To evaluate the effect of neoadjuvant endocrine therapy (NET) on the response rate and the rate of breast conservation surgery (BCS) for ER+ breast cancer. Data Sources: Based on PRISMA guidelines, a librarian-led search of PubMed and Ovid MEDLINE was performed to identify eligible trials published from inception to May 15, 2015...
November 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27315583/randomized-phase-2-neoadjuvant-trial-evaluating-anastrozole-and-fulvestrant-efficacy-for-postmenopausal-estrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-patients-results-of-the-unicancer-carmina-02-french-trial-ucbg
#18
Florence Lerebours, Sofia Rivera, Marie-Ange Mouret-Reynier, Severine Alran, Laurence Venat-Bouvet, Pierre Kerbrat, Remy Salmon, Veronique Becette, Céline Bourgier, Pascal Cherel, Véronique Boussion, Corinne Balleyguier, Fabienne Thibault, Sandrine Lavau-Denes, Jean-Marc Nabholz, Brigitte Sigal, Martine Trassard, Marie-Christine Mathieu, Anne-Laure Martin, Jerome Lemonnier, Emmanuelle Mouret-Fourme
BACKGROUND: Treatment strategies for locally advanced breast cancer in elderly patients too frail to receive neoadjuvant chemotherapy and the introduction of new classes of drugs in the early 2000s have led to the consideration of endocrine therapy as a neoadjuvant treatment for younger hormone receptor (HR)-positive, postmenopausal patients not eligible for primary breast-conserving surgery (BCS). METHODS: This was a multicenter, phase 2, randomized trial designed to evaluate as its primary objective the clinical response rate after up to 6 months of neoadjuvant endocrine therapy (NET) alone in HR-positive/human epidermal growth factor receptor 2 (HER2)-negative patients with 1 mg of anastrozole (arm A) or 500 mg of fulvestrant (arm B)...
October 2016: Cancer
https://www.readbyqxmd.com/read/27313785/effects-of-cdk4-6-inhibition-in-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-cells-with-acquired-resistance-to-paclitaxel
#19
Adriana Priscila Trapé, Shuying Liu, Andrea Carolina Cortes, Naoto T Ueno, Ana Maria Gonzalez-Angulo
Among patients with hormone receptor (HR)-positive breast cancer, those with residual disease after neoadjuvant chemotherapy have a higher risk of relapse and poorer survival than those with a complete response. Previous studies have revealed a correlation between activation of cell cycle-regulating pathways in HR-positive breast cancer, particularly cyclin-dependent kinase (CDK) 4 and 6/cyclin D1 signaling, and resistance to standard therapies. Although CDK4/6 inhibition by palbociclib in combination with endocrine therapy has shown potent antiproliferative effects in HR-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the potential role of palbociclib in re-sensitizing chemotherapy-resistant HR-positive breast cancer is not well defined...
2016: Journal of Cancer
https://www.readbyqxmd.com/read/27275014/deficiency-of-mitochondrial-modulator-mcj-promotes-chemoresistance-in-breast-cancer
#20
Maria J Fernández-Cabezudo, Issam Faour, Kenneth Jones, Devin P Champagne, Mohammed A Jaloudi, Yassir A Mohamed, Ghada Bashir, Saeeda Almarzooqi, Alia Albawardi, M Jawad Hashim, Thomas S Roberts, Haytham El-Salhat, Hakam El-Taji, Adnan Kassis, Dylan E O'Sullivan, Brock C Christensen, James DeGregori, Basel K Al-Ramadi, Mercedes Rincon
Despite major advances in early detection and prognosis, chemotherapy resistance is a major hurdle in the battle against breast cancer. Identifying predictive markers and understanding the mechanisms are key steps to overcoming chemoresistance. Methylation-controlled J protein (MCJ, also known as DNAJC15) is a negative regulator of mitochondrial respiration and has been associated with chemotherapeutic drug sensitivity in cancer cell lines. Here we show, in a retrospective study of a large cohort of breast cancer patients, that low MCJ expression in breast tumors predicts high risk of relapse in patients treated with chemotherapy; however, MCJ expression does not correlate with response to endocrine therapy...
May 19, 2016: JCI Insight
keyword
keyword
119870
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"